Document Detail

Consequences of acute myelogenous leukemia in early pregnancy.
MedLine Citation:
PMID:  332324     Owner:  NLM     Status:  MEDLINE    
Cytarabine and thioguanine therapy for acute myelomonocytic leukemia initiated in the tenth week of pregnancy (with the addition of vincristine and rubidomycin at 17 weeks) led to a short complete remission of the leukemia in a 24-year-old primigravida. This is the first case to be reported in which cytarabine was administered in the first trimester and a prostaglandin termination of pregnancy performed at 20 weeks produced an apparently normal fetus. A review of the literature suggests a slightly less than 50% chance of producing a live healthy baby if acute myelogenous leukemia is diagnosed in the first half of pregnancy, with materna mortality approaching 100% by six months postpartum. Current therapy may improve these figures.
J S Lilleyman; A S Hill; K J Anderton
Related Documents :
21902814 - Physiological remodeling of the maternal uterine circulation during pregnancy.
9454794 - Propranolol elimination by right and left fetal liver: studies in the intact isolated p...
18838394 - Stra13/dec1 and dec2 inhibit sterol regulatory element binding protein-1c in a hypoxia-...
18321514 - Severe liver disease in pregnancy.
23796264 - Fetal thrombotic vasculopathy accompanied by fetal growth restriction.
25351814 - Thrombin generation assay identifies individual variability in responses to low molecul...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cancer     Volume:  40     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1977 Sep 
Date Detail:
Created Date:  1977-11-25     Completed Date:  1977-11-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1300-3     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortion, Therapeutic
Antineoplastic Agents / adverse effects,  therapeutic use*
Cytarabine / therapeutic use
Daunorubicin / therapeutic use
Drug Therapy, Combination
Infant Mortality
Infant, Newborn
Leukemia, Myeloid / drug therapy,  mortality
Leukemia, Myeloid, Acute / complications*
Pregnancy Complications, Hematologic / drug therapy*,  mortality
Pregnancy Trimester, First
Pregnancy Trimester, Second
Thioguanine / therapeutic use
Vincristine / therapeutic use
Reg. No./Substance:
0/Antineoplastic Agents; 0/Teratogens; 147-94-4/Cytarabine; 154-42-7/Thioguanine; 20830-81-3/Daunorubicin; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The epidemiology of bladder cancer: a second look.
Next Document:  Characterization of urothelial carcinoma with respect to the content of carcinoembryonic antigen in ...